Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy?

V. Vančura(Institute of Clinical and Experimental Medicine), R. Poledne(Institute of Clinical and Experimental Medicine), M Gebauerová(Institute of Clinical and Experimental Medicine), Michael Želı́zko(Institute of Clinical and Experimental Medicine), Jan Piťha(Institute of Clinical and Experimental Medicine), Jaroslav A. Hubáček(Institute of Clinical and Experimental Medicine), Martina Langová(Institute of Clinical and Experimental Medicine), Ivan Málek(Institute of Clinical and Experimental Medicine), Zora Dorazilová(Institute of Clinical and Experimental Medicine)
The American Journal of Cardiology
February 1, 1999
10.1016/s0002-9149(98)00889-3
Cited by 32

Related Papers

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
|The Lancet|2014|713
Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data
|BMJ|2014|677
Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization
|Nature Genetics|2014|340
Meta-Analysis of the INSIG2 Association with Obesity Including 74,345 Individuals: Does Heterogeneity of Estimates Relate to Study Design?
|PLoS Genetics|2009|76
A FTO variant and risk of acute coronary syndrome
|Clinica Chimica Acta|2010|65